Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment

Bibliography

• De Fronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care 2012;35(Suppl 1):S11-63
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 2008;22:215-24
   PubMed Web of Science ®Google Scholar
• Andujar-Plata P, Pi-Sunyer X, Laferrere B. Metformin effects revisited. Diabetes Res Clin Pract 2012;95:1-9
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes : a critical review of head-to-head trials. Diabetes Metab 2011; Dec 21 [Epub ahead of print]
   Google Scholar
• Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010;375:1410-12
   PubMed Web of Science ®Google Scholar
• Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71-80
   PubMed Web of Science ®Google Scholar
• Ahren B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011;13:193-203
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011;4:263-71
   PubMedGoogle Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin Drug Metab Toxicol 2010;6:1265-76
   PubMed Web of Science ®Google Scholar
• Halimi S, Schweizer A, Minic B, Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 2008;4:481-92
   PubMedGoogle Scholar
• Anonymous. Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes. Med Lett Drugs Ther 2011;53:21-2
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Saxagliptin and metformin combination therapy. Exp Rev Endocrinol Metab 2011; In press
   Google Scholar
• Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527-33
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Campbell RK. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm 2010;67:1515-25
   PubMed Web of Science ®Google Scholar
• Dhillon S, Weber J. Saxagliptin. Drugs 2009;69:2103-14
   PubMed Web of Science ®Google Scholar
• Kania DS, Gonzalvo JD, Weber ZA. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin Ther 2011;33:1005-22
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Metformin + saxagliptin for type 2 diabetes. Expert Opin Pharmacother 2012;13:139-46
   PubMed Web of Science ®Google Scholar
• Kombiglyze XR (200678Orig1s000) at US Food and Drugs Administration. Available from http://wwwaccessdatafdagov/drugsatfda_docs/nda/2010/200678Orig1s000Namepdf [Last accessed 17 November 2011]
   Google Scholar
• Komboglyze at European Medicines Agency. Available from http://wwwemaeuropaeu/ema/indexjsp?curl=pages/medicines/human/medicines/002059/smops/Positive/human_smop_000279jsp&mid=WC0b01ac058001d127&jsenabled=true [Last accessed 17 November 2011]
   Google Scholar
• AE B-MS. Onglyza (saxagliptin 2.5, 5 mg film-coated tablets: summary of product characteristics [online]. Available from http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001039/WC500044316pdf [Accessed 7 Jun 2011]
   Google Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7
   PubMed Web of Science ®Google Scholar
• Ritz E, Rychlik I, Locatelli F, End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808
   PubMed Web of Science ®Google Scholar
• Middleton RJ, Foley RN, Hegarty J, The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 2006;21:88-92
   PubMed Web of Science ®Google Scholar
• Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009;31:2608-17
   PubMed Web of Science ®Google Scholar
• Whaley-Connell A, Sowers JR, McCullough PA, Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009;53:S11-21
   PubMed Web of Science ®Google Scholar
• Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000;26(Suppl 4):73-85
   PubMedGoogle Scholar
• Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011;12:57-69
   PubMed Web of Science ®Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Medications in the kidney. Acta Clin Belg 2008;63:76-80
   PubMed Web of Science ®Google Scholar
• Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med 2011;123:133-43
   PubMed Web of Science ®Google Scholar
• Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010;33:727-40
   PubMed Web of Science ®Google Scholar
• Pilmore HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton) 2010;15:412-18
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
   PubMed Web of Science ®Google Scholar
• Graham GG, Punt J, Arora M, Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81-98
   PubMed Web of Science ®Google Scholar
• Sambol NC, Chiang J, Lin ET, Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995;35:1094-102
   PubMed Web of Science ®Google Scholar
• Zolk O. Current understanding of the pharmacogenomics of metformin. Clin Pharmacol Ther 2009;86:595-8
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Vormfelde SV, Balen D, The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86:299-306
   PubMed Web of Science ®Google Scholar
• Somogyi A, Stockley C, Keal J, Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987;23:545-51
   PubMed Web of Science ®Google Scholar
• Tsuda M, Terada T, Ueba M, Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 2009;329:185-91
   PubMed Web of Science ®Google Scholar
• Ito S, Kusuhara H, Yokochi M, Competitive inhibition of the luminal efflux by MATEs, but not basolateral uptake by OCT2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 2012;340:393-403
   PubMed Web of Science ®Google Scholar
• Patel CG, Kornhauser D, Vachharajani N, Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes Obes Metab 2011;13:604-14
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Greyber E, Pasternak GA, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;4:CD002967
   PubMed Web of Science ®Google Scholar
• Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503
   PubMed Web of Science ®Google Scholar
• Philbrick AM, Ernst ME, McDanel DL, Metformin use in renal dysfunction: is a serum creatinine threshold appropriate? Am J Health Syst Pharm 2009;66:2017-23
   PubMed Web of Science ®Google Scholar
• Vasisht KP, Chen SC, Peng Y, Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab 2010;12:1079-83
   PubMed Web of Science ®Google Scholar
• Kennedy L, Herman WH. Renal status among patients using metformin in a primary care setting. Diabetes Care 2005;28:922-4
   PubMed Web of Science ®Google Scholar
• Roussel R, Travert F, Pasquet B, Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9
   PubMed Web of Science ®Google Scholar
• Fura A, Khanna A, Vyas V, Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009;37:1164-71
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
   PubMed Web of Science ®Google Scholar
• Boulton DW, Li L, Frevert EU, Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-65
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;13:523-32
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011;65:1230-9
   PubMed Web of Science ®Google Scholar
• Boulton DW, Smith CH, Li L, Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin Drug Investig 2011;31:619-30
   PubMed Web of Science ®Google Scholar
• Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010;8:405-18
   PubMed Web of Science ®Google Scholar
• Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (Minneap) 2011;39:7-21
   PubMedGoogle Scholar
• Doucet J, Chacra A, Maheux P, Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011;27:863-9
   PubMed Web of Science ®Google Scholar
• Jadzinsky M, Pfutzner A, Paz-Pacheco E, Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-22
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Paz-Pacheco E, Allen E, Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011;13:567-76
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Lamanna C, Monami M, Marchionni N, Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011;13:221-8
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Bonomo K, The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010;8:327-37
   PubMed Web of Science ®Google Scholar
• Messaoudi SA, Rongen GA, de Boer RA, The cardioprotective effects of metformin. Curr Opin Lipidol 2011;22:445-53
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Athyros VG, Adamidou F, Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011;13:302-12
   PubMed Web of Science ®Google Scholar
• Monami M, Iacomelli I, Marchionni N, Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35
   PubMed Web of Science ®Google Scholar
• Frederich R, Alexander JH, Fiedorek FT, A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
   PubMed Web of Science ®Google Scholar
• Emslie-Smith AM, Boyle DI, Evans JM, Contraindications to metformin therapy in patients with Type 2 diabetes–a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8
   PubMed Web of Science ®Google Scholar
• Holstein A, Stumvoll M. Contraindications can damage your health–is metformin a case in point? Diabetologia 2005;48:2454-9
   PubMed Web of Science ®Google Scholar
• Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007;24:1160-3
   PubMed Web of Science ®Google Scholar
• Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011;118:c380-3
   PubMed Web of Science ®Google Scholar
• Herrington WG, Levy JB. Metformin: effective and safe in renal disease? Int Urol Nephrol 2008;40:411-17
   PubMed Web of Science ®Google Scholar
• Scale T, Harvey JN. Diabetes, metformin and lactic acidosis. Clin Endocrinol (Oxf) 2011;74:191-6
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Metformin and lactic acidosis. Acta Clin Belg 2011;66:329-31
   PubMed Web of Science ®Google Scholar
• Gudmundsdottir H, Aksnes H, Heldal K, Metformin and antihypertensive therapy with drugs blocking the renin angiotensin system, a cause of concern? Clin Nephrol 2006;66:380-5
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Exp Opin Drug Metab Toxicol 2011;7:1561-76
   PubMed Web of Science ®Google Scholar
• Sweileh WM. Contraindications to metformin therapy among patients with type 2 diabetes mellitus. Pharm World Sci 2007;29:587-92
   PubMed Web of Science ®Google Scholar
• Girman CJ, Kou TD, Brodovicz K, Risk of acute renal failure in patients with type 2 diabetes mellitus. Diabet Med 2011; published on line 2011/10/25; doi: 10.1111/j.1464-5491.2011.03498.x
   PubMedGoogle Scholar